Browse Subject Areas

For Authors

Immunotherapy in Alzheimer’s Disease

Edited by Prashant Tiwari and Sunil Kumar Kadiri
Copyright: 2026 | Expected Pub Date: 2026
ISBN: 9781394336210 | Hardcover |
706 pages
Price: $225 USD

One Line Description
Discover a groundbreaking path forward in the fight against dementia with this vital resource, which bridges the gap between costly drug discovery and the transformative potential of harnessing the immune system to finally target the underlying mechanisms of Alzheimers disease.

Description
Alzheimers disease, which is characterized by a progressive loss of memory and cognitive function, is the most prevalent type of dementia in adults. Despite being widespread, there is currently no permanent treatment for this condition. Current drugs provide only symptomatic relief with serious adverse consequences. The process of discovering new medications in this field is costly and time-consuming, so despite effort on the part of the scientific and pharmaceutical communities, few Alzheimers medications have been created. This book offers a comprehensive exploration of how the immune system can be harnessed to combat one of the most challenging neurodegenerative disorders of our time. It examines the scientific foundations of immunotherapy, including antibodybased strategies, vaccine development, and modulation of innate and adaptive immune responses. It highlights the interplay between amyloid and tau pathology, neuroinflammation, and microglial activation, providing readers with a clear understanding of the mechanisms driving therapeutic innovation. Beyond the laboratory, this volume bridges preclinical research with clinical applications, addressing safety, efficacy, and regulatory considerations. Case studies, emerging technologies, and future directions are presented to illustrate both the promise and the challenges of immunotherapy in Alzheimers care. Designed for neuroscientists, pharmacologists, clinicians, and biotechnology professionals, the book serves as a vital resource for those seeking evidence-based insights into cutting edge therapeutic approaches that may transform the landscape of Alzheimers treatment.

Back to Top

Author / Editor Details
Prashant Tiwari, PhD, is an Associate Professor of Pharmacology in the College of Pharmaceutical Sciences at Dayananda Sagar University, Bengaluru, India, with more than 13 years of teaching and research experience. He has authored six books, edited four books, and co-authored six book chapters, seven patents, and two grants. His research focuses on drug screening, method validation for effective drug delivery to brain cells, drug-induced dyskinesia revalidation, and evaluation of benzimidazole derivatives on the dopaminergic pathway.

K. Sunil Kumar, PhD is an Associate Professor in the Department of Pharmacology in the College of Pharmaceutical Sciences at Dayananda Sagar University, Bengaluru, India with more than 14 years of experience. He has published more than 50 research articles in international journals, one book, and two patents. His research focuses on neuropharmacology and drug interactions.

Table of Contents
Preface
1. Immunotherapy: Unveiling Myths, Shaping Reality, Charting Ideas, and Mapping the Future
K. Trideva Sastri, Dinesh Murugan M., Meghana G.S. and Balamuralidhara V.
1.1 Introduction
1.2 Understanding Immunotherapy in Alzheimer’s Disease
1.2.1 Active Immunotherapy of Alzheimer’s Disease
1.2.2 Passive Immunotherapy of Alzheimer’s Disease
1.3 Unveiling the Myths Surrounding Immunotherapy
1.3.1 Immunotherapy is a Cure for AD
1.3.2 Immunotherapy is Effective for All Stages of Alzheimer’s
1.3.3 Immunotherapy Has No Side Effects
1.3.4 Immunotherapy is a Standalone Solution
1.3.5 Immunotherapy is Widely Accessible
1.3.6 Success in Animal Models Guarantees Human Efficacy
1.4 Shaping the Reality of Immunotherapy
1.4.1 Breakthroughs in Immunotherapy for AD
1.4.1.1 Active Immunotherapy Developments
1.4.1.2 Advances in Passive Immunotherapy
1.4.1.3 Next-Generation Therapies
1.4.2 Clinical Trial Findings
1.5 Charting Ideas: Emerging Trends in Immunotherapy
1.5.1 Biomarker-Driven Therapies
1.5.1.1 Cerebrospinal Fluid (CSF) Biomarkers
1.5.1.2 Blood-Based Biomarkers
1.5.2 Synergistic Approaches Combining Immunotherapy with Other Modalities
1.5.2.1 Non-Pharmacological Interventions in Alzheimer’s Disease
1.6 Mapping the Future of Alzheimer’s Care with Immunotherapy
1.6.1 Patient-Centered Care in Alzheimer’s Disease
1.6.1.1 Role of Monoclonal Antibody Therapies
1.6.1.2 Early Diagnosis and Timely Intervention
1.6.1.3 Personalized Medicine
1.6.2 Strategies to Improve Access and Affordability
1.7 Overcoming Barriers in Translating Research to Clinical Practice in Immunotherapy Treatment of Alzheimer’s Disease
1.7.1 Addressing Gaps between Research and Application
1.7.2 Industry, Academia, and Policy Collaborations
1.7.3 Enhancing Public Awareness and Acceptance
1.8 Conclusion
References
2. Amyloid-β Immunotherapy: Bridging Gaps in Alzheimer’s Strategies
P. K. Sahu, S. K. Prusty, M. Khandai and D. S. Panda
2.1 Introduction
2.2 AD Pathogenesis
2.2.1 Amyloid-Beta (Aβ) Plaques
2.2.2 Tau Neurofibrillary Tangles (NFTs)
2.2.3 Neuroinflammation
2.2.4 Oxidative Stress
2.2.5 Synaptic Dysfunction and Loss
2.3 Advances in AD Treatment
2.3.1 Symptomatic Treatments
2.3.2 Disease-Modifying Therapies (DMTs)
2.4 Advantages and Challenges
2.5 Bridging Gaps in Alzheimer’s Strategies
2.6 Conclusion
2.7 Future Directions
References
3. Advancing Strain-Specific Immunotherapy for Alzheimer’s Disease and Tauopathies: Opportunities and Challenges
Sindhu Priya E. S., Sandhya Vasanth, Tahreen Taj, Mohammed Ameen M. P., Seleshya S. Danam and M. Vijay Kumar
3.1 Introduction
3.1.1 Overview of Alzheimer’s Disease and Tauopathies
3.1.2 The Role of Immunotherapy in Neurodegenerative Diseases
3.1.3 Definition and Importance of Strain-Specific Immunotherapy
3.2 Background on Alzheimer’s Disease and Tauopathies
3.2.1 Pathophysiology of Alzheimer’s Disease
3.2.2 Understanding Tau Protein and Its Role in Neurodegeneration
3.2.2.1 Pathological Changes in Tau Protein
3.2.3 Concept of Strain-Specific Pathology in Alzheimer’s and Tauopathies
3.2.3.1 Cellular Response to Protein Misfolding and Aggregation
3.2.3.2 Structural and Functional Diversity of Tau and Amyloid-Beta Strains
3.3 Current Immunotherapy Approaches for Alzheimer’s Disease
3.3.1 Passive vs. Active Immunotherapy
3.3.2 Antibody-Based Therapeutics
3.3.3 Modulation of Innate Immune Pathways
3.3.4 Emerging Immunotherapeutic Strategies
3.4 Rationale for Strain-Specific Immunotherapy
3.4.1 Diversity of Tau Strains and Their Implications
3.4.2 Advantages of Targeting Specific Strains
3.4.3 Challenges with Broad-Spectrum Immunotherapy
3.5 Opportunities in Strain-Specific Immunotherapy
3.6 Innovative Techniques in Strain-Specific Targeting
3.7 Preclinical and Clinical Studies: Current Status and Findings
3.7.1 Key Preclinical Models and Their Outcome
3.7.1.1 Chemically Modified Models
3.7.1.2 Transgenic Models or Genetically Modified Models
3.7.1.3 Other Animal Models without Genetic Modification or Chemical Induction
3.7.1.4 Animal Models Other than Rodents
3.7.1.5 In Vitro Models
3.7.2 Summary of Ongoing Trials
3.7.2.1 Challenges and Future Directions
3.7.3 Case Studies: Successes and Setbacks in Strain-Specific Immunotherapy
3.7.3.1 Successes in Strain-Specific Immunotherapy
3.7.3.2 Setbacks in Strain-Specific Immunotherapy
3.7.3.3 Challenges and Opportunities
3.8 Future Directions and Emerging Trends
3.8.1 Integration of Genomic and Proteomic Data
3.8.2 Advancements in Neuroimaging for Strain Detection
3.8.3 Role of Multi-Omics in Tailoring Immunotherapy
References
4. Synergistic Approaches: Natural Products, Small Molecules, and Immunotherapy in Brain Disorder Management
Prashant Tiwari, Sunil Kumar Kadiri, Neha Minocha and Astha Singh
4.1 Introduction
4.1.1 Overview of Brain Disorder
4.1.2 Importance of Synergistic Approaches
4.2 Natural Products in Brain Disorder Management
4.2.1 Natural Products Like Herbal Medicines, Nutraceuticals, Marine Compounds: Their Role and Efficacy
4.3 Small Molecules in Brain Disorder Management
4.3.1 Key Small Molecules and Their Efficacy
4.4 Immunotherapy in Brain Disorder Management
4.5 Synergistic Approaches
4.5.1 Synergistic Way into Therapeutics
4.5.2 Combination of Natural Products and Small Molecules
4.5.3 Combination of Natural Products and Immunotherapy
4.5.4 Combination of Immunotherapy and Small Molecules
4.6 Emerging Trends and Innovations in Synergistic Approaches for Brain Disorder Management
4.7 Challenges
4.8 Future Directions
4.9 Conclusion
References
5. Deciphering the Role of Cytokines in Neuroinflammation: Implications for Therapeutic Targeting
Kushagra Nagori, Rashnita Sharma, Anshita Shukla, Reena Deshmukh, Rashi Banchhor, Kartik T. Nakhate, Madhulika Pradhan, Krishna Yadav, Mukesh Kumar Sharma and Aakash Gupta
5.1 Introduction
5.2 CY Families and Their Role in Neuroinflammation
5.2.1 Interleukins (IL-1)
5.2.2 Interleukins (IL-6)
5.2.3 Interleukins
5.2.4 TNF
5.2.5 Interferon (IFN)
5.2.6 Chemokines
5.3 Cellular Sources of CY in the CNS
5.3.1 Microglia
5.3.2 Astrocyte
5.3.3 Oligodendrocytes
5.4 Mechanisms of CY Signaling in the CNS
5.4.1 NF-κB Pathway
5.4.2 MAPK Pathway
5.5 Anti-Inflammatory CY: Regulation and Therapeutic Potential
5.6 CY Dysregulation in Specific Neurodegenerative Disorders
5.6.1 AD
5.6.2 PD
5.6.3 MS
5.7 Therapeutic Targeting of CY
5.7.1 Biologic Types TNF-α Inhibitors
5.8 Conclusion
References
Abbreviations
6. Therapeutic Potential of TREM-1 Modulation in Alzheimer’s Disease
Pragati A. Dongare, Deepak Khobragade, Surendra Agrawal and Mrunali Potbhare
6.1 Introduction
6.1.1 Role of Neuroinflammation in AD Pathogenesis
6.2 TREM-1: Structure and Function
6.3 TREM-1 in Neuroinflammation and AD
6.4 Potential Mechanisms of TREM-1 Modulation in AD Therapy
6.5 Therapeutic Strategies Targeting TREM-1 in AD
6.6 Preclinical and Clinical Studies on TREM-1 in AD
6.7 Challenges and Future Perspectives
6.8 Conclusions
References
7. Personalized Immunotherapy in Brain Disorders: Precision Medicine Insights
Bhaskar Pal, Kushal Roychoudhuri and Moitreyee Chattopadhyay
7.1 Introduction
7.2 Overview of Precision Medicine
7.2.1 Genomic Approaches
7.2.2 Proteomics Approaches
7.2.3 Metabolomic Approaches
7.3 Immunotherapy Technologies
7.3.1 CAR-T Cells
7.3.2 Immune Checkpoint Inhibitors
7.3.2.1 Toripalimab
7.3.2.2 Tisulizumab
7.3.2.3 Sintilimab
7.3.2.4 Pembrolizumab
7.3.2.5 Nivolumab
7.3.2.6 Ipilimumab
7.3.3 Immune Photothermal Therapy
7.3.4 Personalized Vaccines
7.3.5 Immune Cell Therapy
7.4 Personalized Immunotherapy Targeting Cancer-Specific Neoantigen
7.5 Role of Emerging Biomarkers for Personalized Immunotherapies
7.6 Challenges and Limitations of Recent Biomarkers to Identify Response to Immune Therapies
7.7 Use for Brain Diseases
7.8 Technology Innovation
7.8.1 Applications of AI in Immunotherapy
7.8.2 Predictive Analysis in Precision Medicine
7.8.3 Innovations in Immunotherapy
7.9 Clinical Trials
7.10 Challenges and Limitations
7.11 Future Direction
7.12 Conclusion
References
List of Abbreviations
8. Hematological Considerations in Immunotherapy for Alzheimer’s Disease
Ritu Raj Kumar, Rohit Pandey, Sonakshi Antal, Shobha Rani and Md. Sarfraj Alam
Abbreviations
8.1 Introduction
8.1.1 Mechanisms of Immunotherapy and Hematological Impact
8.1.2 Common Hematological Challenges in Immunotherapy for Alzheimer’s Disease
8.1.3 Monitoring and Management Strategies in Immunotherapy for Alzheimer’s Disease
8.2 Patient-Centered Perspectives in Immunotherapy for Alzheimer’s Disease
8.2.1 Regulatory and Ethical Considerations in Immunotherapy for Alzheimer’s Disease
8.2.2 Case Studies and Practical Applications in Immunotherapy for Alzheimer’s Disease
8.3 Future Directions in Immunotherapy for Alzheimer’s Disease
8.4 Conclusion
References
9. Innovative Strategies for Genetic Predispositions in Alzheimer’s: Immunotherapy and Gene Therapy Integration
Shukla Rajendra Kumar, Shah Nishi, Bohra Bhavna, Saxena Bhagawati and Gupta Richa
9.1 Introduction to Alzheimer’s Disease
9.2 Global Statics of Alzheimer’s Disease
9.3 Pathophysiology of Alzheimer’s: Amyloid Plaques, Neurofibrillary Tangles, and Neuroinflammation
9.3.1 The Role of Genetics and Environmental Factors in Alzheimer’s Disease
9.3.2 Key Genes Involved in Alzheimer’s Disease
9.3.3 Genetic and Environmental Interplay in Early-Onset vs. Late-Onset Alzheimer’s
9.4 Current Diagnostic Challenges and the Need for Innovative Approaches
9.5 Gene Therapy: Harnessing Genetic Engineering for Alzheimer’s
9.5.1 Principles of Gene Therapy in Neurodegenerative Disorders
9.5.2 CRISPR-Cas9 and Gene Editing Tools
9.5.3 Gene Delivery Systems: Viral Vectors and Non-Viral Strategies
9.5.4 Stem Cell-Based Gene Therapy
9.6 Immunotherapy: A Promising Frontier in Alzheimer’s Treatment
9.6.1 Overview of Immunotherapy Approaches
9.6.1.1 Active Immunotherapy
9.6.1.2 Passive Immunotherapy
9.6.2 Challenges in Tau-Targeted Immunotherapy
9.6.3 Challenges and Limitations of Current Immunotherapies
9.7 Integrating Immunotherapy and Gene Therapy: A Synergistic Approach
9.7.1 Rationale for Integration: Addressing Multiple Pathological Pathways
9.7.2 Gene Therapy to Enhance Immunotherapy: Boosting Immune Response and Reducing Side Effects
9.8 Preclinical and Clinical Trials: Progress and Challenges
9.8.1 Translational Challenges from Bench to Bedside
9.9 Conclusion: The Road Ahead for Alzheimer’s Treatment
9.9.1 Summarizing the Potential of Integrated Therapies
9.9.2 Addressing Unmet Needs in Alzheimer’s Research
9.9.3 A Vision for the Future of Neurodegenerative Disease Management
References
10. Facilitating Synaptic Repair: Immune System Involvement
Gaurav Mude, Mohammad Tauqeer Sheikh, Shantilal Singune, Sanjay Nagdev and Junaid Tantray
10.1 Introduction to Synaptic Repair
10.1.1 Importance of Synapses in Neural Function
10.1.2 Overview of Synaptic Damage and the Need for Repair
10.2 The Immune System and the Central Nervous System (CNS)
10.2.1 Traditional and Modern Views of Immune Privilege in the CNS
10.2.2 Key Immune Players in Neural Tissues
10.3 Microglia: Sentinels and Sculptors of Synaptic Networks
10.3.1 Functions of Microglia in Monitoring, Pruning, and Repair
10.3.2 Microglial Activation States and Their Effects on Synapses
10.4 Astrocytes and Synaptic Support
10.4.1 Astrocytic Responses to Injury
10.4.2 Role in Maintaining and Restoring Synaptic Homeostasis
10.5 Peripheral Immune Cells in Synaptic Repair
10.5.1 T Cells, Monocytes, and Macrophages
10.5.2 Blood-Brain Barrier Dynamics During Injury
10.6 Molecular Signals Mediating Immune-Synapse Communication
10.6.1 Complement System (e.g., C1q, C3)
10.6.2 Cytokines, Chemokines, and Neurotrophic Factors
10.7 Fractalkine and Other Key Signaling Pathways
10.7.1 Fractalkine-CX3CR1 Axis
10.7.2 Emerging Signaling Molecules Involved in Repair
10.8 Neuroinflammation: Double-Edged Sword
10.8.1 Protective Versus Pathological Inflammation
10.8.2 Factors Tipping the Balance Toward Repair or Degeneration
10.9 Synaptic Dysfunction in Neurodegenerative Diseases
10.9.1 Alzheimer’s Disease, Multiple Sclerosis, and Others
10.9.2 Immune Dysregulation Contributing to Synaptic Loss
10.10 Therapeutic Strategies Targeting Immune Pathways
10.10.1 Immunomodulation for Enhancing Repair
10.10.2 Anti-Inflammatory and Pro-Regenerative Therapies
10.11 Cell-Based Approaches to Promote Synaptic Healing
10.11.1 Stem Cells, Engineered Immune Cells, and Their Applications
10.11.2 Applications of Cell-Based Therapies
10.12 Biomaterials and Immunomodulation
10.12.1 Nanomaterials, Scaffolds, and Immune-Guided Synaptic Repair
10.12.2 Applications of Biomaterials in Synaptic Repair
10.13 Challenges and Risks in Manipulating Immune Responses
10.13.1 Potential Adverse Effects and Long-Term Considerations
10.13.2 Long-Term Considerations
10.14 Future Directions in Synaptic Repair Research
10.14.1 Personalized Medicine Approaches
10.14.2 Emerging Technologies in Synaptic Repair
Conclusion
Acknowledgement
References
11. Exploring Ion Channel-Linked Strategies in Immunotherapy for Neurological Disorders
Hariprasad M.G., Sourav Guha and Moqbel Ali Moqbel Redhwan
11.1 Introduction
11.2 Neurodegenerative Diseases and Their Pathophysiology
11.2.1 Alzheimer’s Disease (AD)
11.2.2 Parkinson’s Disease (PD)
11.2.3 Amyotrophic Lateral Sclerosis (ALS)
11.2.4 Multiple Sclerosis (MS)
11.2.5 Huntington’s Disease (HD)
11.3 Ion Channels and Their Types: Overview
11.3.1 Structure and Function of Ion Channels
11.3.2 Types of Ion Channels
11.3.2.1 Voltage-Gated Ion Channels
11.3.2.2 Ligand-Gated Ion Channels (LGICs)
11.3.2.3 Leak Ion Channels
11.4 Types of Ion Channels in Neurons
11.4.1 Voltage-Gated Na+ Channels (VGSC)
11.4.2 K+ Channels
11.4.3 Voltage-Gated Ca2+ Channels (CaV)
11.4.4 Chloride Channels (ClC-2)
11.4.5 Leak Channels
11.4.6 N-Methyl-D-Aspartate Receptors (NMDARs)
11.4.7 Synaptic Neurotransmitter-Gated Ion Channels
11.5 Ion Channels Present in Different Parts of Neurons
11.5.1 Dendrites
11.5.2 Cell Body
11.5.3 Axon Hillock
11.5.4 Axon Terminals
11.5.5 Nodes of Ranvier
11.6 Role of Ion Channels in Neuronal Excitability, Signaling, and Plasticity
11.6.1 Neuronal Excitability
11.6.2 Signaling and Action Potentials
11.6.3 Neuronal Plasticity
11.7 Immune Signaling in Neurodegeneration
11.8 Immunotherapy
11.8.1 Types
11.9 Immunotherapy in Neurodegenerative Diseases
11.10 Immunotherapy Approaches in Neurodegenerative Diseases
11.11 Inhibiting Pathogenic Immune Signaling
11.12 Intersection of Immunotherapy and Ion Channels
11.13 Immunotherapeutic Agents Targeting Ion Channels in Neurodegenerative Disorders
11.14 Challenges and Limitations of Immunotherapy in Neurodegenerative Disorders
Conclusion
Bibliography
12. Strategies for Inflammation Control: Modulating Microglial Responses
Faizan Khalid, Ashwini Deshpande and D. S. N. B. K. Prasanth
12.1 Introduction
12.1.1 Overview of Inflammation in Neurological Conditions
12.1.2 Significance of Microglia in Neuroinflammation
12.1.3 Objectives of the Chapter
12.2 Microglial Activation and Its Role in Inflammation
12.2.1 Microglial Physiology and Function
12.2.2 Mechanisms of Microglial Activation
12.2.3 Proinflammatory vs. Anti-Inflammatory Microglial States
12.3 Pathophysiological Implications of Microglial Dysregulation
12.3.1 Microglial Dysfunction in Neurodegenerative Diseases
12.3.2 Impact on Neuronal Survival and Synaptic Plasticity
12.3.3 Cross-Talk with Other Immune Cells in the Brain
12.4 Molecular Targets for Modulating Microglial Responses
12.4.1 Toll-Like Receptors (TLRs)
12.4.2 Nuclear Factor Kappa B (NF-κB)
12.4.3 Nod-Like Receptors (NLRs) and Inflammasomes
12.4.4 Cytokines and Chemokines
12.5 Pharmacological Strategies
12.5.1 Anti-Inflammatory Drugs Targeting Microglia
12.5.2 Role of Natural Products in Microglial Modulation
12.5.3 Small Molecule Inhibitors and Monoclonal Antibodies
12.6 Nonpharmacological Interventions
12.6.1 Role of Exercise and Lifestyle Modifications
12.6.2 Dietary Interventions and Nutraceuticals
12.6.3 Neurostimulation Techniques
12.7 Emerging Approaches and Future Directions
12.7.1 Gene Therapy and RNA-Based Technologies
12.7.2 Nanotechnology in Drug Delivery to Microglia
12.7.3 Microbiota‒Gut‒Brain Axis Interactions
12.8 Challenges and Limitations
12.8.1 Translating Preclinical Findings to Clinical Practice
12.8.2 Balancing Pro- and Anti-Inflammatory Responses
12.8.3 Ethical and Technical Challenges in Microglial Research
12.9 Conclusions
References
13. Revolutionizing Neuroprotection: Innovative Lysosomal Targeting Strategies
Ahana Hazra, Rideb Chakraborty, Naureen Afrose, Pratibha Bhowmick and Mithun Bhowmick
13.1 Introduction
13.1.1 Historical Perspective and Summary
13.2 Tackling of Neurodegeneration
13.2.1 Lysosomal Autophagy Pathway Modulation
13.2.2 Regulation of Cellular Lysosomal Metabolism
13.2.3 Targeting Lysosomes Using Nano-Bioengineering Approach
13.3 CNS-Targeting Treatments for Lysosomal Keeping Diseases: Current Advancements and Challenges
13.3.1 Considerations on CNS-Targeting Treatments and Their Drawbacks
13.3.2 Therapeutic Approaches Which Might Address LSD CNS Symptoms
13.3.2.1 Therapy Using Small Molecules
13.3.2.2 Pharmacological Chaperones (PC)
13.3.2.3 Substrate Reduction Therapy
13.3.2.4 Small Compounds for Nonsense Defects in LSDs
13.3.2.5 Cell Therapy
13.3.2.6 CSF-Delivery of ERT Agents
13.3.2.7 Gene-Therapy
13.3.2.8 Gene Therapies In Vivo
13.3.3 Ex Vivo Therapy
13.3.4 Delivery of LSD Treatments Using Nano-Vesicles
13.3.5 The EV-Mediated Delivery of Therapy to Target CNS
13.3.6 Investigating Therapy EVs for the Treatment of CNS Conditions
13.3.7 Liposomal Distribution of LSD Therapies
13.3.8 Quantum Dots
13.3.9 Conclusion
References
14. Ensuring Safety: Immunotherapy and Adverse Effect Management in Cerebrospinal Fluid
Pankaj Malhotra, Neha Minocha, Prashant Tiwari, Sunil Kumar Kadiri and Sampriti Paul
14.1 Introduction
14.1.1 CSF
14.1.2 Physiology of CSF
14.1.3 Blood-Brain Barriers
14.1.4 Functions of the Blood-Brain Barrier
14.2 Role of Immunotherapy in Neurological Disorder
14.2.1 Mechanism of Action
14.2.2 Types of Immunotherapies in Neurological Disorder
14.2.3 ADR Related to Immunotherapy
14.3 Mechanisms of Adverse Effects in Immunotherapy
14.4 Diagnostic Strategies for Adverse Effects
14.4.1 Analysis of Cerebrospinal Fluid
14.4.2 Imaging Modalities
14.4.3 Neurological and Clinical Evaluations
14.4.4 Future Diagnostics
14.5 Management of Immunotherapy in CSF Disorders
14.5.1 Strategies for the Management of Immune-Related Adverse Effects
14.6 Future Development
14.7 Conclusion
References
15. Phytosomes and Blood Barrier Integrity: Implications for Immunotherapy Sustainability
Akanksha and Sajeev Kumar B.
15.1 Introduction
15.1.1 Physicochemical Properties of Phytosomes
15.1.2 Pharmacological Properties
15.1.2.1 Neurodegenerative Diseases
15.1.2.2 Cerebral Ischemia
15.1.2.3 Migraine
15.1.2.4 Nervous System Cancer
15.1.2.5 Pulmonary Fibrosis
15.1.2.6 Chronic Kidney Disease
15.1.3 Preparation of Phytosomes
15.2 Considerations for Drug Delivery to the Brain
15.2.1 Blood–Brain Barrier (BBB)
15.2.2 BBB Structure
15.2.3 BBB Function
15.2.4 Challenges in Drug Delivery
15.2.5 Immunotherapy and Treatment Targets
15.2.6 Mechanism of Phytosome Immunomodulators for BBB Penetration
15.2.7 Phytosomes for CNS Disorders
Conclusion
References
16. Therapeutic Insights: Acetylcholinesterase Inhibitors and Immunotherapy for Alzheimer’s Disease
Rashmi Madhariya, Vikas Kumar, Prince Nikhil Rathore and Alpana Ram
16.1 Introduction
16.2 Acetylcholinesterase Inhibitors (AChEIs)
16.2.1 Key Mechanism Steps
16.2.2 Therapeutic Approaches and Drug Targets for ADs
16.2.2.1 Targeting Ab Protein (Anti-Amyloid Approach)
16.2.2.2 Targeting Amyloid Transport
16.2.2.3 Modulation of Secretase Enzymes
16.2.2.4 Focusing on the Aggregation of Amyloid
16.2.2.5 Targeting Amyloid Clearance
16.2.2.6 Amyloid-Based Vaccination Therapy
16.2.2.7 Targeting Tau Protein
16.2.2.8 Decreased Phosphorylation of Tau Protein
16.2.2.9 Focusing on the Stabilization of Microtubules
16.2.2.10 Focusing on Intracellular Signaling Pathways
16.2.2.11 Adjusting Neurotransmitter Levels: Inhibitors of Acetylcholinesterase
(AChEIs)
16.2.2.12 Modification of GABAergic Neurons
16.2.2.13 NMDA Receptor Antagonism
16.2.2.14 Control of Serotonin Receptor Responses
16.2.2.15 Histamine Activity Modulators
16.2.2.16 Modulation of Adenosine Receptor
16.3 Treatment for ADs Using Immunotherapy
16.3.1 Active Immunization for ADs
16.3.1.1 Immunotherapy Based on Tau Protein
16.3.2 Passive Immunization Therapy for Alzheimer’s Disease
16.4 Comparative Insights: AChEIs vs. Immunotherapy
16.5 Conclusion
References
17. Hormonal Regulation in Immunotherapy for Brain Disorders: Insights and Innovations
Meghana G. S., Chinmayee U. Gowda, K. Trideva Sastri and Balamuralidhara V.
17.1 Introduction
17.1.1 Importance of Hormonal Regulation in Modulating Immune Responses
17.1.2 Key Hormones and Their Roles in Immune Regulation
17.1.2.1 Cortisol and the Hypothalamic-Pituitary-Adrenal (HPA) Axis
17.1.2.2 Estrogen and Gender-Specific Immune Modulation
17.1.2.3 Insulin and Metabolic-Immune Crosstalk
17.1.2.4 Thyroid Hormones and Neuroimmune Regulation
17.1.2.5 Melatonin and Immune Homeostasis
17.2 Hormonal Influence on Immune Function
17.3 Hormones and Brain-Immune Crosstalk
17.3.1 Hypothalamic-Pituitary-Adrenal (HPA) Axis and Its Role in Neuroinflammation
17.3.2 Microglia-Astrocyte Dysregulation
17.3.3 Therapeutic Interventions
17.3.4 The Role of Hormonal Imbalances in Exacerbating Neuroinflammation in AD
17.4 Innovations in Hormonal Regulation for Immunotherapy
17.4.1 Hormone-Based Therapies to Modulate Immune Responses
17.4.1.1 Glucocorticoid Analogues for Controlling Chronic Inflammation
17.4.1.2 Estrogen Replacement Therapy and Its Potential in AD
17.4.1.3 Insights from Preclinical and Clinical Studies
17.5 Synergistic Effects of Combining Hormone Therapy with Immunotherapies
17.5.1 Monoclonal Antibodies Targeting Amyloid-Beta and Tau
17.5.2 T-Cell and B-Cell-Based Therapies
17.6 Tailored Approaches for Gender-Specific and Age-Specific Interventions
17.7 Challenges and Limitations
17.7.1 Risks of Hormonal Therapies
17.7.2 The Complexity of Hormone-Immune Interactions in the Brain
17.7.3 Ethical and Regulatory Considerations
17.8 Future Directions
17.8.1 Development of Personalized Therapies Integrating Hormonal Modulation and Immunotherapy
17.8.2 Potential Role of Biomarkers to Guide Treatment Strategies
17.8.3 Exploring Novel Hormones and Peptides as Immunomodulatory Agents
17.9 Conclusion
References
18. Challenges and Opportunities of Tuberoinfundibular Axis in Brain Disorder Immunotherapy
Pranita Jirvankar, Deepak Khobragade, Surendra Agrawal, Mrunali Potbhare, Prashant Tiwari and Sunil Kumar Kadiri
18.1 Introduction
18.1.1 Overview of the Tuberoinfundibular Axis (TIA)
18.1.2 Neuroanatomy of the Tuberoinfundibular Axis (TIA)
18.2 Hypophyseal Portal System: A Key Neurovascular Link
18.2.1 Anatomy of the Hypophyseal Portal System
18.3 Functional Significance of the Hypophyseal Portal System
18.3.1 Localized Dopamine Delivery to the Anterior Pituitary
18.3.2 Rapid and Precise Neurohormonal Communication
18.3.3 Effective Control of Hormone Levels
18.3.4 Protection from Systemic Interference
18.4 Clinical Implications of the Hypophyseal Portal System
18.4.1 Disorders Affecting the Portal System
18.4.1.1 Pituitary Stalk Interruption Syndrome (PSIS)
18.4.1.2 Hypothalamic Lesions
18.4.1.3 Vascular Diseases
18.4.2 Pharmacological Considerations
18.4.2.1 Dopamine Agonists (e.g., Cabergoline, Bromocriptine)
18.4.2.2 Dopamine Antagonists (e.g., Antipsychotics, Metoclopramide)
18.5 Clinical Relevance of TIA Dysfunction
18.5.1 Disorders Associated with TIA Dysfunction
18.5.1.1 Hyperprolactinemia
18.5.1.2 Hypoprolactinemia
18.5.1.3 Neurodegenerative Diseases (Parkinson’s Disease and TIA Dysfunction)
18.5.1.4 Schizophrenia Treatment and TIA Dysfunction
18.5.2 Therapeutic Strategies for TIA Dysfunction
18.5.2.1 Dopamine Agonists for Hyperprolactinemia and Parkinson’s Disease
18.6 Role of the Tuberoinfundibular Axis (TIA) in Neuroendocrine Regulation
18.6.1 Dopaminergic Control of Prolactin Secretion
18.6.2 Neuroendocrine Integration of TIA with Other Hormonal Systems
18.6.3 TIA in Neuroimmune Regulation
18.7 Significance of the Tuberoinfundibular Axis (TIA) in Brain Disorder Immunotherapy
18.7.1 Dopaminergic Modulation in Brain Disorders
18.7.1.1 Parkinson’s Disease (PD)
18.7.1.2 Schizophrenia and Antipsychotic-Induced Endocrine Dysfunction
18.7.1.3 Depression and Stress-Related Disorders
18.7.2 TIA’s Role in Neuroimmune Interactions and Autoimmune Brain Disorders
18.7.2.1 Multiple Sclerosis (MS) and Neuroinflammation
18.7.2.2 Neuroimmune Crosstalk in Alzheimer’s Disease (AD)
18.7.2.3 Prolactin and Neuroinflammatory Cytokines
18.7.3 Targeting the TIA for Brain Disorder Immunotherapy
18.7.3.1 Dopamine Agonists and Prolactin Modulators
18.7.3.2 Blood-Brain Barrier (BBB)-Permeable Drug Delivery
18.7.3.3 Hormone-Based Immunotherapy
18.8 Neuroanatomy and Function of the Tuberoinfundibular Axis
18.8.1 Structure and Components of the Tuberoinfundibular Axis (TIA)
18.8.1.1 Hypothalamus
18.8.1.2 Pituitary Gland
18.8.2 Dopaminergic Neurons and the Tuberoinfundibular Dopaminergic System
18.8.2.1 Dopaminergic Pathway in the TIA
18.8.2.2 Neurotransmitter Interactions with TIDA Neurons
18.9 Role of the Tuberoinfundibular Axis (TIA) in Hormonal Homeostasis
18.9.1 Dopaminergic Control of Prolactin Secretion
18.9.1.1 Negative Regulation by Dopamine
18.9.1.2 Stimulatory Influences on Prolactin Secretion
18.9.2 Reaction Mechanisms in Hormonal Homeostasis
18.9.3 Physiological and Clinical Implications
18.10 Dopamine and Prolactin Regulation in the Tuberoinfundibular Axis
18.10.1 Dopamine as the Primary Inhibitor of Prolactin Secretion
18.10.2 Prolactin Feedback Regulation (Negative Feedback Loop)
18.11 Immune System Interactions with the Tuberoinfundibular Axis
18.11.1 Neuroimmune Crosstalk in the Tuberoinfundibular Axis (TIA)
18.11.1.1 The Concept of Neuroimmune Crosstalk
18.11.1.2 Key Mediators of Neuroimmune Crosstalk in the TIA
18.11.1.3 Mechanisms of Neuroimmune Crosstalk in the TIA
18.12 Role of Cytokines in Modulating Dopaminergic Activity
18.12.1 Interaction Between Cytokines and Dopaminergic Neurons
18.12.2 Key Cytokines Modulating Dopaminergic Activity
18.12.3 Mechanisms of Cytokine-Dopamine Interaction
18.13 Blood-Brain Barrier and Immune Cell Infiltration in the Tuberoinfundibular Axis
18.14 Opportunities for Therapeutic Interventions
18.15 Potential of Gene Therapy and Cell-Based Approaches
18.16 Case Studies and Current Research Trends
18.17 Future Perspectives and Research Directions
18.18 Conclusion
References
19. Immunotherapy in Alzheimer’s Disease: Regulatory Considerations and Current Clinical Trial Landscape
Mangal Jyoti Das and Pratap Kumar Sahu
19.1 Introduction
19.2 Immunotherapy in Alzheimer’s Disease
19.2.1 Passive Immunotherapy
19.2.2 Active Immunotherapy
19.3 Regulatory Considerations
19.3.1 Target Validation and Biomarker Development
19.3.2 Clinical Trial Design
19.3.3 Safety Concerns
19.3.4 Accelerated Approval Pathways
19.3.5 Combination Therapies
19.3.6 Global Considerations
19.3.7 Ethical and Societal Implications
19.3.8 Post-Marketing Surveillance
19.3.9 Approval Process in India
19.4 Current Clinical Trial Landscape
19.4.1 Sodium Oligomannate
19.4.2 Anti-Amyloid Drugs
19.4.3 Anti-Tau Drugs
19.4.4 Combination Therapies
19.4.5 Anti-Inflammatory and Neuroprotective Drugs
19.4.6 Repurposing of Drugs
19.5 Challenges
19.5.1 Selection of Appropriate Drug Targets
19.5.2 Reliance on Biomarkers and Animal Models in Study Designs
19.5.3 Delayed Treatment Interventions
19.5.4 Dose-Dependent Side Effects
19.5.5 Blood-Brain Barrier (BBB) Permeability Issues
19.5.6 Heterogeneity of Patient Populations
19.6 Conclusion
19.7 Future Directions
19.7.1 Adaptive Trial Designs
19.7.2 Precision Medicine
19.7.3 Global Collaborations
19.7.4 Small-Molecule Therapies
19.7.5 Effective Prevention Strategies
References
Index

Back to Top

Description
Author/Editor Details
Table of Contents
Bookmark this page

Search

Browse Book Series

Browse Subject Areas

For Authors

Immunotherapy in Alzheimer’s Disease